Loading stock data…
$2.08-0.10 (-4.58%)
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.
Ernexa Therapeutics Inc. in the Healthcare sector is trading at $2.08 with a market capitalization of $3M. Wall Street consensus targets $30.00 (1 analysts), implying a +1338.8% move over the next 12 months. The stock is currently near its 52-week low of $2.01, remaining 77.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | $0 | $0 | $0 | $0 |
| Operating Income | -$4.10M↓ | -$3.55M↓ | -$2.09M↓ | -$1.99M↑ | -$2.50M |
| Net Income | -$4.01M↑ | -$5.51M↓ | -$1.50M↓ | -$1.24M↑ | -$3.14M |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflamma...